Graft Versus Host Disease Treatment Advances

Expert panelists elucidate the occurrence of graft vs host disease in patients receiving either stem cell or allogeneic transplantation.

Hematologist/oncologists provide a broad overview of the pharmacologic agents used to prevent graft vs host disease at their institutions.

Shared insight on the pathophysiology of graft vs host disease, with specific regard for differences between acute GVHD vs chronic GVHD.

Centering discussion on a scenario of acute graft vs host disease, expert panelists consider optimal workup of a patient showing signs of GVHD.

Expert hematologist/oncologists share their perspectives on use of biomarkers to help prognosticate graft vs host disease.

Focusing on pharmacologic options, expert panelists review frontline treatment strategies for patients with acute graft vs host disease.

Shared insight on treatment approaches toward patients with acute graft vs host disease who experience partial response to frontline therapy.

After reviewing a clinical scenario of chronic graft vs host disease, panelists consider the importance of different allogeneic transplant types.

Expert hematologist/oncologists highlight challenges in staging chronic graft vs host disease and share strategies to optimize cGHVD assessment.

Comprehensive discussion on the pharmacologic treatment armamentarium available for patients with chronic graft vs host disease.

Closing out their panel on GVHD management, expert hematologist/oncologists share their hope for future evolution in the treatment landscape.

Centering discussion on two clinical scenarios, expert panelists review recent evolutions in the field of graft-vs-host disease management and provide their perspective on optimal treatment strategies.